Torsdag 9 Juli | 01:36:38 Europe / Stockholm
Est. tid*
2027-02-23 08:30 Bokslutskommuniké 2026
2026-10-29 08:30 Kvartalsrapport 2026-Q3
2026-08-20 08:30 Kvartalsrapport 2026-Q2
2026-07-07 - Extra Bolagsstämma 2026
2026-05-08 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2026-05-07 - Årsstämma
2026-05-07 - Kvartalsrapport 2026-Q1
2026-02-20 - Bokslutskommuniké 2025
2026-02-06 - Split LUMITO 500:1
2025-11-27 - Kvartalsrapport 2025-Q3
2025-10-10 - Extra Bolagsstämma 2025
2025-08-11 - Kvartalsrapport 2025-Q2
2025-05-08 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2025-05-07 - Årsstämma
2025-05-07 - Kvartalsrapport 2025-Q1
2025-02-20 - Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-08 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2024-05-07 - Årsstämma
2024-05-07 - Kvartalsrapport 2024-Q1
2024-02-22 - Bokslutskommuniké 2023
2023-10-31 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2023-05-25 - Årsstämma
2023-05-03 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-02 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-30 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2022-05-27 - Årsstämma
2022-05-06 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-24 - Extra Bolagsstämma 2021
2021-10-20 - Kvartalsrapport 2021-Q3
2021-08-18 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2021-05-27 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-03 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2020-05-27 - Årsstämma
2020-04-28 - Kvartalsrapport 2020-Q1
2020-02-17 - Bokslutskommuniké 2019
2019-10-31 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-06-04 - Årsstämma
2019-05-23 - X-dag ordinarie utdelning LUMITO 0.00 SEK
2019-04-30 - Kvartalsrapport 2019-Q1
2019-02-15 - Bokslutskommuniké 2018
LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Lumito är ett svenskt bolag som utvecklar och marknadsför system för vävnads- och biomarköranalys inom digital patologi, byggda på uppkonverterande nanopartikelteknik. Bolaget riktar sig till vårdinrättningar, forskning och läkemedelssektorn. Bolaget bildades 2010 som en spinoff från en forskargrupp vid Lunds universitets avdelning för atomfysik och lasercentrum. Lumito har sitt huvudkontor i Lund.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Lumito appoints Pascal Bamford as new Chair of the Scientific Advisory Board

2026-07-01 08:30:00

Lumito AB (publ) ("Lumito" or the "Company") today announces that Pascal Bamford has been appointed Chair of the Company’s Scientific Advisory Board (SAB). He succeeds Paul Waring, who will continue to serve as a trusted advisor and remain closely engaged with Lumito going forward.

The change reflects Lumito’s transition into an increasingly commercial phase, where Bamford’s extensive industry experience and network are well aligned with the Company’s strategic priorities.
Pascal Bamford brings deep expertise from the pharmaceutical and diagnostics sectors, with a strong track record in translating innovative technologies into commercial opportunities. His experience, including within oncology and antibody-drug conjugate (ADC) development, is highly relevant as Lumito advances its SCIZYS platform toward broader adoption.

“It has been a privilege to serve as Chair of Lumito’s Scientific Advisory Board and to follow the company’s journey. Lumito has built a strong scientific foundation and a highly promising technology platform. I am very pleased to continue supporting the team in an advisory capacity, and I look forward to seeing Pascal take on this role as the company moves further into its commercial phase” , says Paul Waring, previous Chairman of Lumito’s Scientific Advisory Board.

“I am excited to take on this role at such an important stage for Lumito. The SCIZYS platform has significant potential, particularly in supporting the development of next-generation therapies such as ADCs, and I look forward to working closely with the team to realize these opportunities”, says Pascal Bamford, new Chairman of Lumito’s Scientific Adivsory Board.

"Paul has played a key role in shaping Lumito’s scientific direction and supporting the development of our technology. We are very grateful for his contributions and are pleased that he will continue to support the company. At the same time, we are entering a new phase where Pascal’s commercial perspective and network will be instrumental as we accelerate our market activities", says Sanna Wallenborg, CEO of Lumito.